AlphaThera Awarded NIH Grant to Target Pancreatic Cancer
AlphaThera and its partners, Integral Molecular and the University of Pennsylvania, were recently awarded an NIH/NCI SBIR Phase II grant totaling $1.7M over 2 years to work on the project titled “Generation of Antibody-Drug Conjugates by Proximity-based Sortase-mediated Ligation”. The grant was awarded to AlphaThera for the development of highly homogenous antibody drug conjugates (ADC) for the treatment of pancreatic cancer and to identify the optimal approach and lead ADC for continued development into a clinical therapeutic.